JP2017516756A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017516756A5 JP2017516756A5 JP2016562005A JP2016562005A JP2017516756A5 JP 2017516756 A5 JP2017516756 A5 JP 2017516756A5 JP 2016562005 A JP2016562005 A JP 2016562005A JP 2016562005 A JP2016562005 A JP 2016562005A JP 2017516756 A5 JP2017516756 A5 JP 2017516756A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- amino acid
- use according
- seq
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 60
- 229920001184 polypeptide Polymers 0.000 claims description 59
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 59
- 150000001413 amino acids Chemical group 0.000 claims description 40
- 108020001507 fusion proteins Proteins 0.000 claims description 12
- 102000037865 fusion proteins Human genes 0.000 claims description 12
- 101100437153 Rattus norvegicus Acvr2b gene Proteins 0.000 claims description 10
- 208000007056 sickle cell anemia Diseases 0.000 claims description 10
- 108060003951 Immunoglobulin Proteins 0.000 claims description 8
- 102000018358 immunoglobulin Human genes 0.000 claims description 8
- 108010092408 Eosinophil Peroxidase Proteins 0.000 claims description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 6
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 claims description 6
- 206010053648 Vascular occlusion Diseases 0.000 claims description 6
- 230000002378 acidificating effect Effects 0.000 claims description 6
- 208000021331 vascular occlusion disease Diseases 0.000 claims description 6
- 102100040898 Growth/differentiation factor 11 Human genes 0.000 claims description 5
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 claims description 5
- 101000893545 Homo sapiens Growth/differentiation factor 11 Proteins 0.000 claims description 5
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 5
- 238000009120 supportive therapy Methods 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 4
- 239000002738 chelating agent Substances 0.000 claims description 3
- 229910052742 iron Inorganic materials 0.000 claims description 3
- 108091006084 receptor activators Proteins 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 108010074604 Epoetin Alfa Proteins 0.000 claims description 2
- TZXKOCQBRNJULO-UHFFFAOYSA-N Ferriprox Chemical compound CC1=C(O)C(=O)C=CN1C TZXKOCQBRNJULO-UHFFFAOYSA-N 0.000 claims description 2
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 claims description 2
- 206010041660 Splenomegaly Diseases 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 108010084052 continuous erythropoietin receptor activator Proteins 0.000 claims description 2
- 229960001489 deferasirox Drugs 0.000 claims description 2
- FMSOAWSKCWYLBB-VBGLAJCLSA-N deferasirox Chemical compound C1=CC(C(=O)O)=CC=C1N(N\C(N\1)=C\2C(C=CC=C/2)=O)C/1=C\1C(=O)C=CC=C/1 FMSOAWSKCWYLBB-VBGLAJCLSA-N 0.000 claims description 2
- 229960003266 deferiprone Drugs 0.000 claims description 2
- 229960000958 deferoxamine Drugs 0.000 claims description 2
- 229960003388 epoetin alfa Drugs 0.000 claims description 2
- 108010002601 epoetin beta Proteins 0.000 claims description 2
- 229960004579 epoetin beta Drugs 0.000 claims description 2
- 210000003743 erythrocyte Anatomy 0.000 claims description 2
- 125000003473 lipid group Chemical group 0.000 claims description 2
- 229960001046 methoxy polyethylene glycol-epoetin beta Drugs 0.000 claims description 2
- 230000004048 modification Effects 0.000 claims description 2
- 238000012986 modification Methods 0.000 claims description 2
- 230000008816 organ damage Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 27
- 235000001014 amino acid Nutrition 0.000 claims 14
- 108700022380 synthetic erythropoiesis Proteins 0.000 claims 2
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 claims 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 1
- 108010056852 Myostatin Proteins 0.000 claims 1
- 206010040642 Sickle cell anaemia with crisis Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 235000003704 aspartic acid Nutrition 0.000 claims 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 1
- 238000000423 cell based assay Methods 0.000 claims 1
- OEUUFNIKLCFNLN-LLVKDONJSA-N chembl432481 Chemical compound OC(=O)[C@@]1(C)CSC(C=2C(=CC(O)=CC=2)O)=N1 OEUUFNIKLCFNLN-LLVKDONJSA-N 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 230000003319 supportive effect Effects 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 62
- 238000000034 method Methods 0.000 description 47
- 239000005557 antagonist Substances 0.000 description 10
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 4
- 101000886562 Homo sapiens Growth/differentiation factor 8 Proteins 0.000 description 4
- 208000007502 anemia Diseases 0.000 description 4
- 108010059616 Activins Proteins 0.000 description 2
- 102100026818 Inhibin beta E chain Human genes 0.000 description 2
- 239000000488 activin Substances 0.000 description 2
- 108010023082 activin A Proteins 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 108010019673 Darbepoetin alfa Proteins 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010019842 Hepatomegaly Diseases 0.000 description 1
- 101000899361 Homo sapiens Bone morphogenetic protein 7 Proteins 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 206010022840 Intraventricular haemorrhage Diseases 0.000 description 1
- 206010065973 Iron Overload Diseases 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 206010037596 Pyelonephritis Diseases 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 206010038935 Retinopathy sickle cell Diseases 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 206010041648 Splenic infarction Diseases 0.000 description 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 208000034698 Vitreous haemorrhage Diseases 0.000 description 1
- 108010023079 activin B Proteins 0.000 description 1
- 206010051895 acute chest syndrome Diseases 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 229960005029 darbepoetin alfa Drugs 0.000 description 1
- 108010067416 epoetin delta Proteins 0.000 description 1
- 229950002109 epoetin delta Drugs 0.000 description 1
- 108010090921 epoetin omega Proteins 0.000 description 1
- 229950008767 epoetin omega Drugs 0.000 description 1
- 230000000913 erythropoietic effect Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 208000032253 retinal ischemia Diseases 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020005711A JP7315487B2 (ja) | 2014-04-18 | 2020-01-17 | 赤血球レベルを増加させ、そして鎌状赤血球症を処置するための方法 |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461981519P | 2014-04-18 | 2014-04-18 | |
| US61/981,519 | 2014-04-18 | ||
| US201461984393P | 2014-04-25 | 2014-04-25 | |
| US61/984,393 | 2014-04-25 | ||
| US201462011482P | 2014-06-12 | 2014-06-12 | |
| US62/011,482 | 2014-06-12 | ||
| US201462036066P | 2014-08-11 | 2014-08-11 | |
| US62/036,066 | 2014-08-11 | ||
| US201462088374P | 2014-12-05 | 2014-12-05 | |
| US62/088,374 | 2014-12-05 | ||
| PCT/US2015/026415 WO2015161220A1 (en) | 2014-04-18 | 2015-04-17 | Methods for increasing red blood cell levels and treating sickle-cell disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020005711A Division JP7315487B2 (ja) | 2014-04-18 | 2020-01-17 | 赤血球レベルを増加させ、そして鎌状赤血球症を処置するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017516756A JP2017516756A (ja) | 2017-06-22 |
| JP2017516756A5 true JP2017516756A5 (OSRAM) | 2018-05-31 |
| JP6649895B2 JP6649895B2 (ja) | 2020-02-19 |
Family
ID=54324622
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016562005A Active JP6649895B2 (ja) | 2014-04-18 | 2015-04-17 | 赤血球レベルを増加させ、そして鎌状赤血球症を処置するための方法 |
| JP2020005711A Active JP7315487B2 (ja) | 2014-04-18 | 2020-01-17 | 赤血球レベルを増加させ、そして鎌状赤血球症を処置するための方法 |
| JP2021130588A Pending JP2021175755A (ja) | 2014-04-18 | 2021-08-10 | 赤血球レベルを増加させ、そして鎌状赤血球症を処置するための方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020005711A Active JP7315487B2 (ja) | 2014-04-18 | 2020-01-17 | 赤血球レベルを増加させ、そして鎌状赤血球症を処置するための方法 |
| JP2021130588A Pending JP2021175755A (ja) | 2014-04-18 | 2021-08-10 | 赤血球レベルを増加させ、そして鎌状赤血球症を処置するための方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20150361163A1 (OSRAM) |
| EP (2) | EP3808778A1 (OSRAM) |
| JP (3) | JP6649895B2 (OSRAM) |
| AP (1) | AP2016009549A0 (OSRAM) |
| AU (2) | AU2015247459A1 (OSRAM) |
| BR (1) | BR112016024319B1 (OSRAM) |
| CA (1) | CA2962197C (OSRAM) |
| ES (1) | ES2845650T3 (OSRAM) |
| MA (1) | MA52909A (OSRAM) |
| MX (2) | MX388380B (OSRAM) |
| WO (1) | WO2015161220A1 (OSRAM) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
| EP3811965A1 (en) | 2005-11-23 | 2021-04-28 | Acceleron Pharma, Inc. | Activin-actriia antagonists in use for promoting bone growth |
| US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| TW201940502A (zh) | 2007-02-02 | 2019-10-16 | 美商艾瑟勒朗法瑪公司 | 衍生自ＡｃｔＲＩＩＢ的變體與其用途 |
| KR20200054317A (ko) | 2007-02-09 | 2020-05-19 | 악셀레론 파마 인코포레이티드 | 액티빈-ＡｃｔＲⅡＡ 길항제 및 암 환자에서 골 생장을 촉진시키기 위한 이의 용도 |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| HUE051137T2 (hu) | 2008-08-14 | 2021-03-01 | Acceleron Pharma Inc | GDF-csapdák |
| US8178488B2 (en) | 2009-06-08 | 2012-05-15 | Acceleron Pharma, Inc. | Methods for increasing thermogenic adipocytes |
| EP2440577A4 (en) | 2009-06-12 | 2013-01-23 | Acceleron Pharma Inc | SHORTEN ACTRIIB FC FUSION PROTEINS |
| US8710016B2 (en) | 2009-11-17 | 2014-04-29 | Acceleron Pharma, Inc. | ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy |
| US10195249B2 (en) | 2012-11-02 | 2019-02-05 | Celgene Corporation | Activin-ActRII antagonists and uses for treating bone and other disorders |
| CN107135646B (zh) | 2014-06-13 | 2022-03-15 | 阿塞勒隆制药公司 | 用于治疗溃疡的方法和组合物 |
| MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
| MA41119A (fr) * | 2014-12-03 | 2017-10-10 | Acceleron Pharma Inc | Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique |
| JP2018501307A (ja) | 2014-12-03 | 2018-01-18 | セルジーン コーポレイション | アクチビン−ＡｃｔＲＩＩアンタゴニスト及び貧血を治療するための使用 |
| PT3286206T (pt) | 2015-04-22 | 2021-04-01 | Biogen Ma Inc | Novas proteínas híbridas bloqueadoras de ligando actriib para tratar doenças de desgaste muscular |
| CA2986432A1 (en) | 2015-05-20 | 2016-11-24 | Celgene Corporation | In vitro cell culture methods for beta-thalassemia using activin type ii receptor ligand traps |
| WO2017079591A2 (en) | 2015-11-04 | 2017-05-11 | Acceleron Pharma Inc. | Methods for increasing red blood cell levels and treating ineffective erythropoiesis |
| US11065277B2 (en) | 2015-11-09 | 2021-07-20 | Albert Einstein College Of Medicine | Method of ameliorating side effects of sickle cell disease treatments |
| US10550170B2 (en) | 2015-11-23 | 2020-02-04 | Acceleron Pharma Inc. | Methods for treating vascular eye disorders with actrii antagonists |
| GB2550114A (en) * | 2016-05-03 | 2017-11-15 | Kymab Ltd | Methods, regimens, combinations & antagonists |
| SI3496739T1 (sl) * | 2016-07-15 | 2021-06-30 | Acceleron Pharma Inc. | Sestave, ki zajemajo polipeptide actriia, za uporabo pri zdravljenju pljučne hipertenzije |
| AU2017302282B2 (en) | 2016-07-27 | 2024-07-25 | Acceleron Pharma Inc. | Methods and compositions for treating myelofibrosis |
| CN110198743B (zh) * | 2016-10-05 | 2023-07-18 | 艾科赛扬制药股份有限公司 | 用于治疗肾脏疾病的组合物和方法 |
| EP3523328A4 (en) | 2016-10-05 | 2020-04-01 | Acceleron Pharma Inc. | VARIANT ACTRIIB PROTEINS AND USES THEREOF |
| JOP20190085A1 (ar) | 2016-10-20 | 2019-04-17 | Biogen Ma Inc | طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة |
| WO2018089706A2 (en) | 2016-11-10 | 2018-05-17 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
| AU2018214629A1 (en) * | 2017-02-06 | 2019-08-22 | Acceleron Pharma Inc. | Compositions and methods for treating heart failure |
| WO2019094751A1 (en) | 2017-11-09 | 2019-05-16 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
| KR20200109330A (ko) | 2018-01-12 | 2020-09-22 | 케로스 테라퓨틱스, 인크. | 액티빈 수용체 유형 iib 변이체 및 그의 사용 방법 |
| AU2019266314B2 (en) | 2018-05-09 | 2025-05-15 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
| CN114761013A (zh) | 2019-09-27 | 2022-07-15 | 迪斯克医药公司 | 治疗骨髓纤维化和相关病症的方法 |
| WO2021189010A1 (en) | 2020-03-20 | 2021-09-23 | Keros Therapeutics, Inc. | Methods of using activin receptor type iib variants |
| KR20230012539A (ko) | 2020-05-13 | 2023-01-26 | 디스크 메디슨, 인크. | 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체 |
| US12186370B1 (en) | 2020-11-05 | 2025-01-07 | Celgene Corporation | ACTRIIB ligand trap compositions and uses thereof |
| EP4541805A1 (en) * | 2022-06-15 | 2025-04-23 | PeptiDream Inc. | Peptide and peptide-containing agent |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5080891A (en) | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| ATE102631T1 (de) | 1988-11-11 | 1994-03-15 | Medical Res Council | Klonierung von immunglobulin sequenzen aus den variabelen domaenen. |
| US5198346A (en) | 1989-01-06 | 1993-03-30 | Protein Engineering Corp. | Generation and selection of novel DNA-binding proteins and polypeptides |
| US5096815A (en) | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
| WO1990008822A1 (en) | 1989-02-03 | 1990-08-09 | Genetics Institute, Inc. | Erythropoietin receptor |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5707796A (en) | 1990-06-11 | 1998-01-13 | Nexstar Pharmaceuticals, Inc. | Method for selecting nucleic acids on the basis of structure |
| US5763177A (en) | 1990-06-11 | 1998-06-09 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex |
| US5270163A (en) | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
| US5567588A (en) | 1990-06-11 | 1996-10-22 | University Research Corporation | Systematic evolution of ligands by exponential enrichment: Solution SELEX |
| ATE318832T1 (de) | 1990-06-11 | 2006-03-15 | Gilead Sciences Inc | Verfahren zur vervendung von nukleinsäureliganden |
| US5580737A (en) | 1990-06-11 | 1996-12-03 | Nexstar Pharmaceuticals, Inc. | High-affinity nucleic acid ligands that discriminate between theophylline and caffeine |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| CA2095633C (en) | 1990-12-03 | 2003-02-04 | Lisa J. Garrard | Enrichment method for variant proteins with altered binding properties |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| FI941572A7 (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä |
| DE69334255D1 (de) | 1992-02-06 | 2009-02-12 | Novartis Vaccines & Diagnostic | Marker für Krebs und biosynthetisches Bindeprotein dafür |
| US5677196A (en) | 1993-05-18 | 1997-10-14 | University Of Utah Research Foundation | Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays |
| US5525490A (en) | 1994-03-29 | 1996-06-11 | Onyx Pharmaceuticals, Inc. | Reverse two-hybrid method |
| US5885574A (en) | 1994-07-26 | 1999-03-23 | Amgen Inc. | Antibodies which activate an erythropoietin receptor |
| US5814565A (en) | 1995-02-23 | 1998-09-29 | University Of Utah Research Foundation | Integrated optic waveguide immunosensor |
| NZ306767A (en) | 1995-04-11 | 2000-03-27 | Univ Johns Hopkins | Method of identifying molecular interactions employing counterselection and at least two hybrid molecules or two hybrid systems |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6699843B2 (en) | 1995-06-07 | 2004-03-02 | Gilead Sciences, Inc. | Method for treatment of tumors using nucleic acid ligands to PDGF |
| US6011577A (en) | 1997-06-30 | 2000-01-04 | Polaroid Corporation | Modular optical print head assembly |
| WO1999010364A1 (en) | 1997-08-29 | 1999-03-04 | Human Genome Sciences, Inc. | Follistatin-3 |
| US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
| BR9813365A (pt) | 1997-12-05 | 2004-06-15 | Scripps Research Inst | Método para produção e humanização de um anticorpo monoclonal de rato |
| US6335155B1 (en) | 1998-06-26 | 2002-01-01 | Sunesis Pharmaceuticals, Inc. | Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules |
| EP1141708A1 (en) | 1998-12-28 | 2001-10-10 | Sunesis Pharmaceuticals Inc. | Identifying small organic molecule ligands for binding |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| ATE322681T1 (de) | 1999-01-21 | 2006-04-15 | Metamorphix Inc | Inhibitoren für wachstumdifferenzierungsfaktor und ihre anwendungen |
| DE60042021D1 (de) | 1999-07-29 | 2009-05-28 | Gilead Sciences Inc | Nukleinsäureliganden für den hepatozytischen wachstumsfaktor/dispersionsfaktor (hgf/sf) und seines c-met rezeptors |
| CA2393869A1 (en) | 1999-12-15 | 2001-06-21 | Genetech,Inc. | Shotgun scanning, a combinatorial method for mapping functional protein epitopes |
| MXPA02010011A (es) | 2000-04-11 | 2003-04-25 | Genentech Inc | Anticuerpos multivalentes y usos para los mismos. |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| ES2405944T3 (es) | 2000-11-30 | 2013-06-04 | Medarex, Inc. | Ácidos nucleicos que codifican las secuencias de inmunoglobulina humana reorganizadas a partir de ratones transcromoscómicos transgénicos zadas |
| CA2488441C (en) | 2002-06-03 | 2015-01-27 | Genentech, Inc. | Synthetic antibody phage libraries |
| US20050079574A1 (en) | 2003-01-16 | 2005-04-14 | Genentech, Inc. | Synthetic antibody phage libraries |
| US20070135336A1 (en) | 2003-09-15 | 2007-06-14 | De Kretser David | Follistatin isoforms and uses thereof |
| MXPA06011199A (es) | 2004-03-31 | 2007-04-16 | Genentech Inc | Anticuerpos anti-tgf-beta humanizados. |
| US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
| WO2005100402A1 (en) | 2004-04-13 | 2005-10-27 | F.Hoffmann-La Roche Ag | Anti-p-selectin antibodies |
| ES2426005T3 (es) | 2004-07-23 | 2013-10-18 | Acceleron Pharma Inc. | Polipéptidos del receptor ACTRII, procedimientos y composiciones |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| CN101065151B (zh) | 2004-09-23 | 2014-12-10 | 健泰科生物技术公司 | 半胱氨酸改造的抗体和偶联物 |
| US8067562B2 (en) | 2005-11-01 | 2011-11-29 | Amgen Inc. | Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1 |
| WO2007056441A2 (en) | 2005-11-07 | 2007-05-18 | Genentech, Inc. | Binding polypeptides with diversified and consensus vh/vl hypervariable sequences |
| EP3811965A1 (en) | 2005-11-23 | 2021-04-28 | Acceleron Pharma, Inc. | Activin-actriia antagonists in use for promoting bone growth |
| WO2007064919A2 (en) | 2005-12-02 | 2007-06-07 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
| AR060871A1 (es) | 2006-05-09 | 2008-07-16 | Genentech Inc | Union de polipeptidos con supercontigos optimizados |
| WO2008030367A2 (en) | 2006-09-01 | 2008-03-13 | The General Hospital Corporation | Selective myostatin inhibitors |
| US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| EP2599495A1 (en) | 2007-02-01 | 2013-06-05 | Acceleron Pharma, Inc. | Activin-ActRIIa Antagonists and Uses for Treating or Preventing Breast Cancer |
| TW201940502A (zh) | 2007-02-02 | 2019-10-16 | 美商艾瑟勒朗法瑪公司 | 衍生自ＡｃｔＲＩＩＢ的變體與其用途 |
| KR20200054317A (ko) | 2007-02-09 | 2020-05-19 | 악셀레론 파마 인코포레이티드 | 액티빈-ＡｃｔＲⅡＡ 길항제 및 암 환자에서 골 생장을 촉진시키기 위한 이의 용도 |
| CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
| EP2318028B1 (en) * | 2008-06-26 | 2020-02-19 | Acceleron Pharma Inc. | Antagonists of soluble activin-actriia and uses for increasing red blood cell levels |
| HUE051137T2 (hu) * | 2008-08-14 | 2021-03-01 | Acceleron Pharma Inc | GDF-csapdák |
| CN107837390A (zh) * | 2011-10-17 | 2018-03-27 | 阿塞勒隆制药公司 | 用于治疗无效性红细胞生成的方法和组合物 |
| AU2012364736A1 (en) * | 2011-12-19 | 2014-07-24 | Amgen Inc. | Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof |
| EP2912462B1 (en) * | 2012-10-24 | 2019-08-07 | Celgene Corporation | Biomarker for use in treating anemia |
-
2015
- 2015-04-17 EP EP20197941.6A patent/EP3808778A1/en not_active Withdrawn
- 2015-04-17 JP JP2016562005A patent/JP6649895B2/ja active Active
- 2015-04-17 ES ES15779814T patent/ES2845650T3/es active Active
- 2015-04-17 MX MX2016013635A patent/MX388380B/es unknown
- 2015-04-17 US US14/689,477 patent/US20150361163A1/en not_active Abandoned
- 2015-04-17 BR BR112016024319-6A patent/BR112016024319B1/pt active IP Right Grant
- 2015-04-17 MA MA052909A patent/MA52909A/fr unknown
- 2015-04-17 AP AP2016009549A patent/AP2016009549A0/en unknown
- 2015-04-17 CA CA2962197A patent/CA2962197C/en active Active
- 2015-04-17 WO PCT/US2015/026415 patent/WO2015161220A1/en not_active Ceased
- 2015-04-17 AU AU2015247459A patent/AU2015247459A1/en not_active Abandoned
- 2015-04-17 EP EP15779814.1A patent/EP3131931B1/en active Active
-
2016
- 2016-10-17 MX MX2021014709A patent/MX2021014709A/es unknown
-
2020
- 2020-01-17 JP JP2020005711A patent/JP7315487B2/ja active Active
- 2020-08-10 US US16/989,505 patent/US20210188955A1/en not_active Abandoned
-
2021
- 2021-04-20 AU AU2021202382A patent/AU2021202382B2/en active Active
- 2021-08-10 JP JP2021130588A patent/JP2021175755A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017516756A5 (OSRAM) | ||
| JP2017523140A5 (OSRAM) | ||
| Kandasamy et al. | TGF-β signaling: a therapeutic target to reinstate regenerative plasticity in vascular dementia? | |
| JP6796695B2 (ja) | 成長因子モジュレーションのための組成物および方法 | |
| JP7685737B2 (ja) | 疾患の治療または予防に用いるためのファクター１およびファクター２タンパク質、およびその阻害剤 | |
| JP4947717B2 (ja) | アンジオポエチン様４タンパク質のインヒビター、組み合わせ、およびそれらの使用 | |
| Paleolog | The vasculature in rheumatoid arthritis: cause or consequence? | |
| JP6865585B2 (ja) | 成長分化因子１５（ｇｄｆ−１５）に対するモノクローナル抗体およびがん悪液質およびがんを処置するためのその使用 | |
| KR102366682B1 (ko) | 죽상경화증의 치료를 위한 세마포린-4d 결합 분자의 용도 | |
| JP2017101068A5 (OSRAM) | ||
| US20210340238A1 (en) | TGFß1 INHIBITORS AND USE THEREOF | |
| JP2017537921A5 (OSRAM) | ||
| JP2019522022A5 (OSRAM) | ||
| US9333257B2 (en) | FGFR1 antibodies and treatment of cancer | |
| JP2017509647A5 (OSRAM) | ||
| JP2016500704A (ja) | 細胞シグナル伝達を変調するための組成物及び方法 | |
| JP2010522208A (ja) | 安定な抗体処方物 | |
| Brekken et al. | VEGF–VEGF receptor complexes as markers of tumor vascular endothelium | |
| US20160060307A1 (en) | Human ferritin-derived fusion polypeptide | |
| JP2003534384A (ja) | 神経保護性ペプチド | |
| US20160215045A1 (en) | VEGFA/Ang2 Compounds | |
| DK2916866T3 (en) | FORMULATION FOR BISPECIFIC T-CELL SENSORS (BITES) | |
| KR20180134876A (ko) | 인간화 항 clever-1 항체 및 이의 용도 | |
| JP5139058B2 (ja) | 新形成または新生脈管構造の検出、画像化および処置のための血管標的 | |
| JP6865581B2 (ja) | 神経学的疾患又は神経変性疾患に有用な新規抗体 |